Inovio Pharmaceuticals (INO) Stock: Spiking On Positive Study Results

0

Inovio Pharmaceuticals Inc (NASDAQ: INO)

Inovio Pharmaceuticals is having an incredibly strong day in the market today, and for good reason. The company released data with regard to a vaccine that’s proving to be promising. Today, we’ll talk about what we’re seeing from the stock, why, and what we will be watching with regard to INO ahead.




What We’re Seeing From INO

As mentioned above, Inovio Pharmaceuticals is having an incredibly strong start to the trading session. Since the market opened, the stock has been flying well above the green line. Currently (10:03), INO is trading at $7.81 per share after a gain of $0.38 per share or 5.11% thus far today.

Why We’re Seeing The Gains

As soon as we noticed that INO was heading up in value at such a pace, the CNA Finance team started to research to see what was behind the uptrend. We believe we’ve found the cause. Early this morning, Inovio Pharmaceuticals released a report with regard to a vaccine it is working on.

In the report, we learned that the vaccine, designed to protect against Zika, has completed a study among non-human primates. In the study, INO found that the Zika vaccine did indeed protect the animals from the infection as well as brain damage and death! Of course, this is overwhelmingly positive news which caused excitement among investors.

What We’ll Be Watching Ahead

First and foremost, the CNA Finance team plans to keep a close eye on the development of the Zika Vaccine. If INO is able to pull this one together, it could be massive. However, we are watching several things with regard to the stock. At the end of the day, the company has an incredibly strong pipeline, of which, the Zika Vaccine is actually a small piece. All in all, we’ll be keeping a close eye on this entire pipeline for a glimpse of what we can expect to see next out of Inovio Pharmaceuticals stock.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required



[adrotate group=”4″]



[Image Courtesy of Wikimedia]

LEAVE A REPLY

Please enter your comment!
Please enter your name here